Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI

Yuiuf, Salim
September 2005
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p43
Academic Journal
The article focuses on a study by researcher K. Malmberg and colleagues, which found that intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. The study found that in patients with type 2 diabetes and acute myocardial infarction, an insulin-glucose regimen with long-term insulin control was not better than an insulin regimen with standard glucose control for improving survival. In patients with diabetes, no strong evidence exists that lowering glucose prevents macrovascular disease, although it can clearly prevent microvascular disease.


Related Articles

  • How metformin controls blood glucose. Morris, David // GP: General Practitioner;3/25/2002, p56 

    Focuses on the efficacy of metformin in regulating glucose in the circulation. Administration of metformin in type-2 diabetic patients; Reduction of myocardial infarction; Mechanism of action.

  • oral hypoglycaemic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p413 

    The article presents information on oral hypoglycaemic drugs which are usually synthetic agents taken by mouth to reduce the levels of glucose (sugar) in the bloodstream and are used mainly in the treatment of Type II diabetes (non-insulin-dependent diabetes mellitus; maturity-onset diabetes)...

  • log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Hermans, Michel P.; Ahn, Sylvie A.; Rousseau, Michel F. // Cardiovascular Diabetology;2010, Vol. 9, p88 

    Background: T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack of screening methods consensus. Aim: To establish the prevalence and...

  • A Functional Tyr1306Cys Variant in LARG Is Associated With Increased Insulin Action in Vivo. Kovacs, Peter; Stumvoll, Michael; Bogardus, Clifton; Hanson, Robert L.; Baier, Leslie J. // Diabetes;May2006, Vol. 55 Issue 5, p1497 

    Diminished insulin sensitivity is a characteristic feature of type 2 diabetes. Inhibition of insulin action, resulting in reduced skeletal muscle glucose uptake, is mediated in part through stimulation of RhoA activity. One regulator of RhoA activity is leukemia-associated Rho guanine nucleotide...

  • Treat all type 2 diabetes patients as if they had a history of prior MI. Haffner, S.M.; Lehto, S. // Geriatrics;Oct98, Vol. 53 Issue 10, p91 

    Reports that according to the authors of a study in Finland, aggressive treatment should be administered to cardiovascular risk factors in patients with type 2 diabetes who have not had a myocardial infarction (MI). Amount of participants in the study; Age range of the participants; Comparison...

  • Ask Doctor Cory. SerVaas, Cory // Turtle;Jul/Aug2003, Vol. 25 Issue 4, p34 

    Addresses questions about diseases, such as heart attack and type 2 diabetes.

  • Risks of treating diabetes 2. Napoli, Maryann // Center for Medical Consumers;Aug2011, p1 

    The article discusses the risks attendant to treating type 2 diabetes. A meta-analysis, which gathered clinical results from 13 randomized tests and published in the "British Medical Journal," shows that the drugs can cause risks leading to non-fatal or fatal heart diseases for diabetics who had...

  • Third-line diabetes drugs offer comparable results.  // Pulse;5/25/2011, Vol. 71 Issue 19, p9 

    The article discusses a study on the efficiency of third-line diabetes drugs on patients with type 2 diabetes wherein researchers reveal that there is no evident difference between drug classification on patients using metformin and sulfonylurea when added with a third agent.

  • Troglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus. Plosker, G.L.; Faulds, D. // Drugs;Mar1999, Vol. 57 Issue 3, p409 

    Troglitazone is the first of a new group of oral antidiabetic drugs, the thiazolidinediones, and is indicated for the treatment of patients with type 2 (non-insulin-dependent) diabetes mellitus. Troglitazone acts by enhancing the effects of insulin at peripheral target sites and, unlike the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics